Head and Neck Cancer

Robert L. Ferris, Yael Flamand, Gregory S. Weinstein, et al.
The study authors conclude that in intermediate risk HPV+ OPC primary transoral surgery and reduced PORT (reduced dose postoperative radiotherapy) retained outstanding oncologic outcomes at 35 months follow up, with favorable quality of live and functional outcomes. Clinical trial information: NCT01898494.
Ari Rosenberg, Nishant Agrawal, Alexander T. Pearson, et al.
The study authors conclude that Nivo/nab-paclitaxel/carboplatin followed by risk/response adaptive de-escalated treatment in locoregionally advanced HPV+ OPC demonstrates excellent survival outcomes with reduced toxicity and enteral feeding rates, including high-risk disease. They demonstrated that Induction chemoimmunotherapy has a high rate of deep clinical response. They conclude, that this treatment represents a promising de-escalation approach that incorporates anti-PD1 in the definitive setting. A high pCR rate was observed following nivo/nab-paclitaxel/carboplatin. Clinical trial information: NCT03107182
Danny Rischin, Madeleine T. King, Lizbeth M. Kenny, et al.
The study authors show that for patients with low risk HPV-associated oropharyngeal cancer, radiotherapy and cetuximab had inferior failure-free survival without improvement in symptom burden or toxicity compared to radiotherapy and weekly cisplatin. They conclude that radiotherapy and cisplatin remain the standard of care. Clinical trial information: NCT01855451
Stuart J. Wong, Pedro A. Torres-Saavedra, Nabil F. Saba, et al.
The study authors show that adding lapatinib to the radiation-cisplatin platform did not improve progression-free or overall survival in unselected non-HPV HN. They conclude that dual EGFR, HER-2 inhibition does not appear to enhance the effects of chemoradiation. Although they showed that accrual to a non-HPV HN specific trial is feasible, they recommend that new strategies must be investigated to improve the outcome for this poor prognosis HN population.
Julie E. Bauman, Nabil F. Saba, Denise Roe, et al.
Ficlatuzumab is an IgG1 anti-HGF monoclonal antibody. The study authors show that the well-tolerated Ficlatuzumab plus cetuximab combination met the primary progression-free survival endpoint in pan-refractory, advanced HNSCC with notable activity in HPV- HNSCC, warranting phase III investigation. Clinical trial information: NCT03422536
Alexandra Jackovich, Barbara J. Gitlitz, Justin Wayne Wong Tiu-lim, et al.
Soluble EphB4-Alb blocks bidirectional signaling of EphB4, which provides tumor cell survival and EphrinB2, which inhibits immune cell invasion. The study authors show now that 
  • sEphB4-Alb was well tolerated in combination with PD-1 antibody.
  • sEphB4-Alb was associated with increased immune response to tumor, when combined with PD-1 antibody.
  • sEphB4-Alb appears to have substantial activity (including complete remission) when combined with PD-1 antibody in relapsed/refractory HPV negative HN SCC.
Clinical trial information: NCT03049618
Christine H. Chung, Nabil F. Saba, Conor Ernst Steuer, et al.
The study authors conclude that the trial met its primary endpoint of 1-year overall survival. Their data indicate the combination of cetuximab and nivolumab is safe and effective in patients with previously untreated incurable R/M HNSCC. Clinical trial information: NCT03370276
Feng Liu, Shengnan Fu, Yanzhu Chen, et al.
The study authors conclude that among patients with locoregionally advanced nasopharyngeal carcinoma diffusion-weighted MR imaging-guided dose-painting radiotherapy plus chemotherapy is associated with a considerable survival benefit. This goes without increasing toxicity, as compared with standard CT-based radiotherapy plus chemotherapy. Clinical trial information: ChiCTR1800015779.
Nancy Y. Lee, Eric Jeffrey Sherman, Heiko Schöder, et al.
The study authors show that major de-escalation to 30Gy using patient-specific treatment response based on hypoxia resolution resulted in excellent locoregional control with significant toxicity reduction. Clinical trial information: NCT03323463